AKT1 and prostate carcinoma: Further support that MYC dysregulates glucose metabolism was provided when mass spectrometry-based metabolomic analysis was used to compare the metabolic profiles of established transgenic mouse models of MYC- or AKT-driven prostate cancer (Ellwood-Yen et al., 2003; Majumder et al., 2003), as well as human prostate cancer samples that had been profiled for activated phospho-AKT and MYC levels.